Market Place
Sourcing Support
All News #Library
Biotech
QurAlis Shows Disease Progression Impact In ANQUR Trial
23 Feb 2026 //
PHARMIWEB
Quralis Confirms QRL-101 Target Engagement in ALS
29 Dec 2025 //
BUSINESSWIRE
QurAlis To Present At J.P. Morgan Healthcare Conference
18 Dec 2025 //
PHARMIWEB
Quralis To Present QRL-101, Ph 1 Trial Data At AES 2025 Meeting
02 Dec 2025 //
BUSINESSWIRE
Quralis Attends Piper Sandler 37th Annual Healthcare Conference
20 Nov 2025 //
BUSINESSWIRE
QurAlis Names Manoj Malhotra, M.D., Chief Medical Officer
10 Nov 2025 //
BUSINESS WIRE
Quralis To Present at November Investor Conferences
03 Nov 2025 //
BUSINESSWIRE
QurAlis to Attend Investor Conferences in September
20 Aug 2025 //
BUSINESSWIRE
QurAlis Licenses Fragile X Tech for First Disease-Modifying Drug
15 May 2025 //
BUSINESSWIRE
QurAlis Reports Ph1 Data On QRL-101 Biomarkers In ALS, Epilepsy
12 Mar 2025 //
PR NEWSWIRE
QurAlis` Trial of QRL-201 in ALS Advances to Dose Finding Phase
19 Nov 2024 //
PR NEWSWIRE
QurAlis Grants Lilly Exclusive Global License For QRL-204 In ALS, FTD
03 Jun 2024 //
PR NEWSWIRE
QurAlis to Present Data Showing Link Between TDP-43 Pathology and Role of UNC13A
06 Sep 2023 //
PR NEWSWIRE
QurAlis Receives CTA in EU for QRL-201
06 Jun 2023 //
PR NEWSWIRE
QurAlis enters ALS space with precision therapy approach
07 Apr 2023 //
CLINICAL TRIALS ARENA
QurAlis Reveals Program Targeting UNC13A RNA Incorporating its FlexASO Platform
20 Mar 2023 //
PR NEWSWIRE
ALS biotech QurAlis gets $88M boost from four pharmas for pair of PhI studies
09 Mar 2023 //
ENDPTS
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.